Late-life cognitive decline represents a major public health challenge driven by intersecting neurodegenerative and vascular mechanisms. Although the apolipoprotein E epsilon 4 allele remains the most recognized genetic risk factor for Alzheimer disease, accumulating evidence indicates that cardiometabolic genetic risk also exerts a profound influence on long-term brain health. Cardiovascular and metabolic disorders frequently co-occur with neurodegenerative processes, complicating clinical diagnoses in older patients. Therefore, determining whether inherited vascular vulnerabilities accelerate neurodegenerative pathology or directly trigger cognitive deterioration provides vital insights for preventive clinical medicine.

Evaluating Cardiometabolic Genetic Risk and Dementia Pathogenesis

Cardiometabolic disorders and neurodegenerative conditions share multiple biological pathways, including sustained neuroinflammation, microvascular endothelial impairment, and defective clearance of cerebral toxic proteins. Consequently, medical researchers have sought to determine whether inherited vascular traits initiate cognitive decline or merely exacerbate existing neurodegeneration. In this context, polygenic risk scores provide a robust method to evaluate lifetime inherited susceptibility to cardiovascular disorders. These scores aggregate thousands of lead single nucleotide polymorphisms identified through large-scale genome-wide association studies.

Furthermore, evaluating hereditary vascular factors helps clinicians distinguish primary neurotoxic cascades from secondary ischemic damage. Chronic arterial stiffening and microcirculatory shear stress promote cerebral white matter disease and microvascular infarcts, which progressively exhaust cognitive reserve. However, earlier genomic datasets frequently failed to evaluate the interplay between cardiometabolic genetic risk and cognitive trajectories in ethnically diverse cohorts. Addressing this scientific limitation is crucial, especially as physicians manage growing populations of older adults who present with concurrent metabolic syndromes and cognitive decline.

The REGARDS Cohort and Multi-Ancestry Genetic Architecture

To investigate these genomic interactions, researchers evaluated comprehensive longitudinal data from the Reasons for Geographic and Racial Differences in Stroke study, known as the REGARDS cohort. Notably, this prospective investigation recruited a substantial proportion of Black participants, who have historically faced significant underrepresentation in neurogenetics research. By analyzing up to 8,818 participants with an average age of 63.7 years, the study offered robust statistical power to examine multi-ancestry genomic architecture across diverse backgrounds.

In addition, the research team constructed detailed polygenic risk scores across twelve distinct cardiometabolic conditions. These traits included coronary artery disease, ischemic stroke, type 2 diabetes, venous thromboembolism, atrial fibrillation, lipid subclasses, and systolic, diastolic, and pulse pressure measurements. Participants completed recurring cognitive evaluations using validated screening batteries to track changes over time. Furthermore, investigators reviewed comprehensive national mortality records to determine whether dementia contributed directly or secondarily to participant death. Consequently, this study design established an ideal framework to distinguish early cognitive changes from terminal neurodegenerative outcomes.

Pulse Pressure Polygenic Scores Predict Dementia Mortality

The study demonstrated a notable and statistically significant association between vascular genetics and fatal dementia outcomes. Specifically, participants possessing a higher polygenic risk score for pulse pressure exhibited a 16 percent increase in dementia as a contributing cause of death. This association remained statistically robust after adjusting for chronological age, biological sex, and principal components of genetic ancestry.

Interestingly, researchers observed no significant association between the pulse pressure polygenic score and incident cognitive impairment during follow-up screening. This distinction indicates that inherited pulse pressure traits may primarily accelerate late-stage neurodegenerative disease progression rather than initiate early cognitive deficits. Furthermore, pulse pressure serves as a recognized clinical marker of central arterial stiffness and loss of vascular compliance. When major conduit arteries stiffen, pulsatile pressure waves transmit unchecked into delicate cerebral microvessels, damaging perivascular units and compromising glymphatic clearance. Therefore, genetic susceptibility to elevated pulse pressure creates persistent hemodynamic stress that accelerates terminal neurodegenerative pathology.

The Interplay of APOE Variants and Ancestral Backgrounds

Alongside cardiometabolic polygenic predictors, the investigators evaluated established apolipoprotein E risk alleles and local genetic ancestry at the APOE locus. The apolipoprotein E epsilon 4 allele represents the strongest single-gene vulnerability for sporadic Alzheimer disease across global populations. However, its phenotypic penetrance and clinical effect size vary considerably depending on ancestral chromosomal contexts.

Moreover, local genetic ancestry can alter lipid transport efficiency, microvascular integrity, and microglial activation surrounding amyloid plaques. The analysis confirmed that while the epsilon 4 allele consistently predicted cognitive impairment, ancestral backgrounds introduced subtle variations in clinical expression. Furthermore, these findings emphasize that polygenic risk profiles operate concurrently with major Mendelian risk variants rather than in isolation. Consequently, modern predictive frameworks must combine both major locus genotyping and broad polygenic profiling to ensure accurate risk estimation across diverse patient populations.

Translating Genomic Insights into Routine Clinical Practice

These findings offer valuable guidance for physicians managing older patients presenting with concurrent cardiovascular risk factors. Specifically, clinicians should recognize elevated pulse pressure and arterial stiffness as critical modifiable targets in the preservation of cognitive function. Although polygenic risk profiling remains primarily a research tool, identifying vascular contributors to dementia reinforces the vital importance of aggressive midlife cardiovascular risk factor management.

Furthermore, prompt lifestyle modifications and optimal pharmacological therapy can significantly improve arterial compliance and mitigate pulsatile vascular trauma. Healthcare providers should prioritize early detection of isolated systolic hypertension, promote heart-healthy dietary patterns, and recommend routine aerobic exercise to preserve vascular elasticity. Moreover, therapeutic strategies that reduce central arterial stiffness may delay late-stage neurodegenerative progression in high-risk individuals. Therefore, integrating cardiovascular prevention with cognitive health management provides an actionable pathway to improve patient longevity and preserve late-life cognition.

What is the clinical significance of pulse pressure in dementia risk?

Elevated pulse pressure reflects systemic arterial stiffness and compromised vascular compliance. Over time, pulsatile hemodynamic stress damages fragile cerebral microvessels, disrupting the blood-brain barrier and accelerating neurodegeneration. Consequently, persistent vascular pulsatility significantly increases susceptibility to cerebral amyloid angiopathy, ischemic white matter injury, and late-stage dementia-related mortality.

How do polygenic risk scores improve upon traditional clinical assessments?

Polygenic risk scores aggregate cumulative effects of hundreds of small-effect genetic variants across the entire human genome. While conventional clinical risk scores capture current phenotypic states, polygenic scores reveal lifetime biological susceptibility. Therefore, integrating genomic profiling with clinical metrics allows physicians to identify vulnerable individuals decades before overt clinical manifestations emerge.

Why is diverse population representation vital in neurogenetic research?

Historically, genomic association studies primarily analyzed cohorts of European ancestry, which restricted their generalizability across diverse global groups. Different racial populations frequently exhibit distinct linkage disequilibrium architectures, allele frequencies, and background environmental interactions. Consequently, evaluating diverse cohorts ensures accurate risk stratification algorithms and equitable clinical applicability for patients across varied ethnic demographics.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Kim D et al. Influence of Cardiometabolic and Alzheimer Disease Genetics on Cognitive-Related Outcomes in a Diverse Population. Neurology. 2026 Jul 14. doi: 10.1212/WNL.0000000000218163. PMID: 42234953.


2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.


3. Morrill VN, Pike JR, Hu J, et al. Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study. Neurology. 2026;107(1):e218280.